Overview
Universal Brain, backed by $7.9 million in seed funding, has achieved a major milestone with FDA 510(k) clearance of its UB ERP System on July 13, 2026. The clearance validates the company's approach to objective, EEG-based mental health assessment and positions it for rapid commercial scale-up.
The Investment Thesis
Investors backed Universal Brain on the premise that psychiatry's reliance on subjective questionnaires is a solvable problem. By developing a portable, dry-electrode EEG system that measures event-related potentials (ERPs) in under five minutes, the company offers a biological measurement tool that fits into existing clinical workflows.
Product and Market
The UB ERP System is designed for deployment in primary care and psychiatric offices, where it can provide objective data points for conditions including depression, ADHD, and anxiety. The US mental health diagnostics market exceeds $5 billion annually, and an objective screening tool could become standard of care.
What's Next
With FDA clearance in hand, Universal Brain is expected to pursue additional funding to support commercial launch, reimbursement negotiations, and expansion of its clinical evidence base.
